Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics.

The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.

It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine.

The company is headquartered in Toronto, Canada.